BRPI0608395A2 - composição farmacêutica sólida que compreende telitromicina - Google Patents

composição farmacêutica sólida que compreende telitromicina

Info

Publication number
BRPI0608395A2
BRPI0608395A2 BRPI0608395-1A BRPI0608395A BRPI0608395A2 BR PI0608395 A2 BRPI0608395 A2 BR PI0608395A2 BR PI0608395 A BRPI0608395 A BR PI0608395A BR PI0608395 A2 BRPI0608395 A2 BR PI0608395A2
Authority
BR
Brazil
Prior art keywords
telithromycin
pharmaceutical composition
solid pharmaceutical
weight
pharmaceutically acceptable
Prior art date
Application number
BRPI0608395-1A
Other languages
English (en)
Inventor
Christian Desesquelle
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0608395(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0608395A2 publication Critical patent/BRPI0608395A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçãO FARMACêUTICA SóLIDA QUE COMPREENDE TELITROMICINA. A patente de invenção refere-se a uma composição farmacêutica sól ida que compreende telitromicina ou um de seus sais de adição com um ácido farmaceuticamente aceitável, como princípio ativo, caracterizada pelo fato de que ela compreende, em relação ao peso total da composição: telitromicina ou um de seus sais de adição com um ácido farmaceuticamente aceitável, de acordo com uma proporção em telitromicina compreendida entre 0,1 e 80 % em peso, e pelo menos um agente diluente de comportamento plástico, de acordo com uma proporção de 10 a 50 % em peso. A presente invenção provê vantajosamente um comprimido de telitromicina tendo um tamanho sensivelmente reduzido, porém com dosagem igual de telitromicina, e apresentando propriedades mecânicas melhoradas.
BRPI0608395-1A 2005-02-25 2006-02-23 composição farmacêutica sólida que compreende telitromicina BRPI0608395A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501936A FR2882522B1 (fr) 2005-02-25 2005-02-25 Composition pharmaceutique solide comprenant de la telithromycine
PCT/FR2006/000411 WO2006090067A1 (fr) 2005-02-25 2006-02-23 Composition pharmaceutique solide comprenant de la telithromycine

Publications (1)

Publication Number Publication Date
BRPI0608395A2 true BRPI0608395A2 (pt) 2009-12-29

Family

ID=35106715

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608395-1A BRPI0608395A2 (pt) 2005-02-25 2006-02-23 composição farmacêutica sólida que compreende telitromicina

Country Status (29)

Country Link
US (2) US20080113020A1 (pt)
EP (1) EP1855695B1 (pt)
JP (1) JP5063368B2 (pt)
KR (1) KR101346453B1 (pt)
CN (1) CN101180064B (pt)
AR (1) AR053144A1 (pt)
AT (1) ATE486633T1 (pt)
AU (1) AU2006217814B2 (pt)
BR (1) BRPI0608395A2 (pt)
CA (1) CA2598210A1 (pt)
CY (1) CY1111129T1 (pt)
DE (1) DE602006017975D1 (pt)
DK (1) DK1855695T3 (pt)
ES (1) ES2354906T3 (pt)
FR (1) FR2882522B1 (pt)
HK (1) HK1120412A1 (pt)
HR (1) HRP20110089T1 (pt)
IL (1) IL185251A (pt)
ME (1) ME01936B (pt)
MX (1) MX2007010405A (pt)
MY (1) MY145394A (pt)
PL (1) PL1855695T3 (pt)
PT (1) PT1855695E (pt)
RS (1) RS51578B (pt)
RU (1) RU2371184C2 (pt)
SI (1) SI1855695T1 (pt)
TW (1) TWI371280B (pt)
UY (1) UY29403A1 (pt)
WO (1) WO2006090067A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2882522B1 (fr) 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine
CN102499936B (zh) * 2011-12-01 2013-06-26 西北农林科技大学 一种复方泰利霉素纳米乳口服液及其制备方法
JP6112696B1 (ja) * 2015-10-05 2017-04-12 富山化学工業株式会社 ソリスロマイシンを含む錠剤
RU2018129198A (ru) * 2016-01-12 2020-02-13 Вокхардт Лимитед Фармацевтические композиции
WO2020021574A1 (en) * 2018-07-27 2020-01-30 Wockhardt Limited Pharmaceutical compositions and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US6985594B1 (en) * 1999-06-15 2006-01-10 Hearing Enhancement Co., Llc. Voice-to-remaining audio (VRA) interactive hearing aid and auxiliary equipment
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
KR100487137B1 (ko) * 2002-07-12 2005-05-03 주식회사 하이닉스반도체 반도체 소자의 제조 방법
US20040013737A1 (en) * 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
WO2004009059A1 (en) * 2002-07-19 2004-01-29 Aventis Pharma S.A. Taste masked oral composition of telithromycin
WO2004017925A2 (en) * 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
EP1545453B1 (en) * 2002-08-29 2009-11-18 ActivBiotics Pharma LLC Rifalazil for treating infections of clostridium difficile
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
EP1613333A1 (en) * 2003-04-04 2006-01-11 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
FR2882522B1 (fr) 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine

Also Published As

Publication number Publication date
AU2006217814A1 (en) 2006-08-31
IL185251A (en) 2012-10-31
UY29403A1 (es) 2006-10-02
CN101180064B (zh) 2010-09-22
DK1855695T3 (da) 2011-02-21
ATE486633T1 (de) 2010-11-15
DE602006017975D1 (de) 2010-12-16
IL185251A0 (en) 2008-02-09
HK1120412A1 (en) 2009-04-03
TW200640472A (en) 2006-12-01
EP1855695A1 (fr) 2007-11-21
RU2371184C2 (ru) 2009-10-27
KR20070106581A (ko) 2007-11-01
KR101346453B1 (ko) 2014-01-02
ES2354906T3 (es) 2011-03-21
MY145394A (en) 2012-02-15
AR053144A1 (es) 2007-04-25
EP1855695B1 (fr) 2010-11-03
FR2882522B1 (fr) 2007-04-13
PL1855695T3 (pl) 2011-04-29
PT1855695E (pt) 2011-01-19
CN101180064A (zh) 2008-05-14
MX2007010405A (es) 2007-10-17
ME01936B (en) 2016-10-19
FR2882522A1 (fr) 2006-09-01
CY1111129T1 (el) 2015-06-11
AU2006217814B2 (en) 2011-08-11
RU2007135367A (ru) 2009-03-27
CA2598210A1 (fr) 2006-08-31
WO2006090067A1 (fr) 2006-08-31
JP5063368B2 (ja) 2012-10-31
RS51578B (en) 2011-08-31
US20080113020A1 (en) 2008-05-15
JP2008531529A (ja) 2008-08-14
US8962021B2 (en) 2015-02-24
SI1855695T1 (sl) 2011-02-28
US20130344151A1 (en) 2013-12-26
TWI371280B (en) 2012-09-01
HRP20110089T1 (hr) 2011-03-31

Similar Documents

Publication Publication Date Title
AR054581A1 (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
TW200733968A (en) Stabilized lanthanum carbonate compositions
BR112014027116A2 (pt) formulação de anticorpo
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
BR112012018384A2 (pt) composição farmacêutica sólida com intensificadores e métodos de preparação da mesma.
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
WO2010100200A3 (en) Lyophilised antibody formulation
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
BRPI0508833A (pt) formulações galênicas de compostos orgánicos
BRPI0413361B8 (pt) comprimido seguro contra abuso termo-moldado por extrusão sem descoramento
BRPI0518191A (pt) métodos e composições para reduzir a toxicidade de um composto farmacêutico
BRPI0922804B8 (pt) composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável
BRPI0608395A2 (pt) composição farmacêutica sólida que compreende telitromicina
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
AR056835A1 (es) Composicion que contiene oligosacaridos
WO2007064620A3 (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists
BRPI0916885B8 (pt) composição farmacêutica
FR2887150B1 (fr) Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
BR0116060A (pt) Composição farmacêutica de dronedarona para administração parenteral
BRPI0510820A (pt) composição farmacêutica, forma unitária de dosagem e seus usos
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
AR055658A1 (es) Composiciones fungicidas
CY1120050T1 (el) Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]